July 23 (Reuters) - Boston Scientific ( BSX ) raised its

annual profit forecast on Wednesday, banking on strong demand

for its heart devices, and trimmed its expectation for

tariff-related costs to half of the previously projected amount.

Shares of the company rose 4.8% in morning trading

following the results.

"Based on the current schedule of expected tariffs, we now

anticipate a full-year headwind of about $100 million, down from

a $200 million estimate," CFO John Monson said during a call

with analysts.

The company expects to offset the remaining tariff impact

through strong sales performance, favorable product mix and

spending control, Monson added.

A rise in surgical procedures has boosted sales for

medical device makers such as Boston Scientific ( BSX ), helping counter

broader concerns about healthcare spending.

Executives credited strong trial results and expanded

product indications for fueling physician adoption of key

cardiovascular devices such as Watchman and Farapulse, the

firm's main growth drivers that saw steady quarterly demand.

The company said the proposed rules by the Centers for

Medicare & Medicaid Services regarding certain cardiac

procedures would further benefit its technologies.

Farapulse, which is approved in the U.S. for some patients

with intermittent atrial fibrillation, competes with Johnson &

Johnson's ( JNJ ) Varipulse and Medtronic's ( MDT ) PulseSelect

in the pulsed field ablation (PFA) market.

Rival Johnson & Johnson ( JNJ ) last week posted strong medtech

sales, aided by its heart devices, Varipulse and Trupulse.

JP Morgan analyst Robbie Marcus said the profit forecast

raise was larger than many had expected, especially given Boston

Scientific ( BSX ) is now moving past the initial U.S. rollout of

Farapulse.

"That said, the outlook still appears conservative to

us," Marcus added.

Boston Scientific ( BSX ) now expects 2025 adjusted profit of $2.95

to $2.99 per share, up from its prior view of $2.87 to $2.94.

It posted adjusted profit of 75 cents per share for the

second quarter, topping analysts' average estimate of 72 cents,

according to LSEG.